The role of P2X receptors in bone biology

Current Medicinal Chemistry

Volumn 22, Issue 7, 2015, Pages 902-914

  Jorgensen N R ^a,b   Syberg, S ^a   Ellegaard, M ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bone biology; Bone formation; Bone resorption; Bone turnover; Osteoblast; Osteoclast; Osteocyte; Osteoporosis; P2X receptor; Single nucleotide polymorphism

Indexed keywords

PURINERGIC P2X RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ALLELE; ARTICLE; BONE; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; CANCER RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; GAIN OF FUNCTION MUTATION; GENETIC ANALYSIS; HUMAN; MEDICAL RESEARCH; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN FUNCTION; SPINE FRACTURE; ANIMAL; BONE DENSITY; CYTOLOGY; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE DENSITY; CELL DIFFERENTIATION; HUMANS; RECEPTORS, PURINERGIC P2X;

EID: 84926310553     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141215094749     Document Type: Article

References (105)

1. Gartland A.; Hipskind RA.; Gallagher JA.; Bowler WB. Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J. Bone Miner. Res., 2001, 16, 846-856.
2. Brandao-Burch A.; Key ML.; Patel JJ.; Arnett TR.; Orriss IR. The P2X7 Receptor is an Important Regulator of Extracellular ATP Levels. Front Endocrinol (Lausanne), 2012, 3, 41.
3. Kringelbach TM.; Aslan D.; Novak I.; Schwarz P.; Jorgensen NR. UTP-induced ATP release is a fine-tuned signalling pathway in osteocytes. Purinergic Signal, 2014, 10, 337-47.
4. Ralevic V.; Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev., 1998, 50, 413-92.
5. Buell G.; Collo G.; Rassendren F. P2X receptors: an emerging channel family. Eur. J. Neurosci.; 1996, 8, 2221-2228.
6. Jacobson KA.; Jarvis MF.; Williams M. Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem., 2002, 45, 4057-4093.
7. Hoebertz A.; Townsend-Nicholson A.; Glass R.; Burnstock G.; Arnett TR. Expression of P2 receptors in bone and cultured bone cells. Bone, 2000, 27, 503-510.
8. Orriss IR.; Knight GE.; Ranasinghe S.; Burnstock G.; Arnett TR. Osteoblast responses to nucleotides increase during differentiation. Bone, 2006, 39, 300-309.
9. Orriss IR.; Key ML.; Brandao-Burch A.; Patel JJ.; Burnstock G.; Arnett TR. The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors. Bone, 2012, 51, 389-400.
10. Liu PS.; Chen CY. Butyl benzyl phthalate suppresses the ATPinduced cell proliferation in human osteosarcoma HOS cells. Toxicol. Appl. Pharmacol., 2010, 244, 308-314.
11. Ihara H.; Hirukawa K.; Goto S.; Togari A. ATP-stimulated interleukin-6 synthesis through P2Y receptors on human osteoblasts. Biochem. Biophys. Res. Commun., 2005, 326, 329-334.
12. Ling G.; Ovbiagele B. Oral antiplatelet therapy in the secondary prevention of atherothrombotic events. Am. J. Cardiovasc Drugs, 2009, 9, 197-209.
13. Alqallaf SM.; Evans BA.; Kidd EJ. Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. Br. J. Pharmacol, 2009, 156, 1124-1135.
14. Zippel N.; Limbach CA.; Ratajski N.; Urban C.; Luparello C.; Pansky A. Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev., 2012, 21, 884-900.
15. Nakamura E.; Uezono Y.; Narusawa K.; Shibuya I.; Oishi Y.; Tanaka M. ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. Am. J. Physiol. Cell Physiol., 2000, 279, C510-C519.
16. Jorgensen NR.; Henriksen Z.; Brot C.; Eriksen EF.; Sorensen OH.; Civitelli R. Human osteoblastic cells propagate intercellular calcium signals by two different mechanisms. J. Bone Miner. Res., 2000, 15, 1024-1032.
17. Ke HZ.; Qi H.; Weidema AF.; Zhang Q.; Panupinthu N.; Crawford DT. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol. Endocrinol, 2003, 17, 1356-1367.
18. Naemsch LN.; Weidema AF.; Sims SM.; Underhill TM.; Dixon SJ. P2X(4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J. Cell Sci., 1999, 112, 4425-4435.
19. Cheng SL.; Zhang SF.; Nelson TL.; Warlow PM.; Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif. Tissue Int., 1994, 55, 356-362.
20. Buckley KA.; Hipskind RA.; Gartland A.; Bowler WB.; Gallagher JA. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappaB ligand. Bone, 2002, 31, 582-590.
21. Orriss I.; Syberg S.; Wang N.; Robaye B.; Gartland A.; Jorgensen N. Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed), 2011, 3, 1038-1046.
22. Modderman WE.; Weidema AF.; Vrijheid-Lammers T.; Wassenaar AM.; Nijweide PJ. Permeabilization of cells of hemopoietic origin by extracellular ATP4-: elimination of osteoclasts, macrophages, and their precursors from isolated bone cell populations and fetal bone rudiments. Calcif. Tissue Int., 1994, 55, 141-150.
23. Jorgensen NR.; Henriksen Z.; Sorensen OH.; Eriksen EF.; Civitelli R.; Steinberg TH. Intercellular Calcium Signaling Occurs between Human Osteoblasts and Osteoclasts and Requires Activation of Osteoclast P2X7 Receptors. J. Biol. Chem., 2002, 277, 7574-7580.
24. Gartland A.; Buckley KA.; Bowler WB.; Gallagher JA. Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif. Tissue Int., 2003, 73, 361-369.
25. Naemsch LN.; Dixon SJ.; Sims SM. Activity-dependent development of p2x7 current and ca2+ entry in rabbit osteoclasts. J. Biol. Chem., 2001, 276, 39107-39114.
26. Li J.; Liu D.; Ke HZ.; Duncan RL.; Turner CH. The P2X7 Nucleotide Receptor Mediates Skeletal Mechanotransduction. J. Biol. Chem. 2005, 280, 42952-42959.
27. Kringelbach TM.; Aslan D.; Novak I.; Ellegaard M.; Syberg S.; Kristiansen KA. Fine-tuned ATP signals are acute mediators in osteocyte mechanotransduction. Bone, 2014, in press.
28. Nishii N.; Nejime N.; Yamauchi C.; Yanai N.; Shinozuka K.; Nakabayashi T. Effects of ATP on the intracellular calcium level in the osteoblastic TBR31-2 cell line. Biol. Pharm. Bull. 2009, 32, 18-23.
29. Orriss IR.; Key ML.; Hajjawi MO.; Arnett TR. Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralisation. PLoS One, 2013, 8, e69057.
30. Nakamura E.; Uezono Y.; Narusawa K.; Shibuya I.; Oishi Y.; Tanaka M. ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. Am. J. Physiol. Cell Physiol. 2000, 279, C510-C519.
31. Adinolfi E.; Pizzirani C.; Idzko M.; Panther E.; Norgauer J.; Di VF. P2X(7) receptor: Death or life? Purinergic Signal, 2005, 1, 219-227.
32. Panupinthu N.; Rogers JT.; Zhao L.; Solano-Flores LP.; Possmayer F.; Sims SM. P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J. Cell Biol., 2008, 181, 859-871.
33. McBeath R.; Pirone DM.; Nelson CM.; Bhadriraju K.; Chen CS. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell, 2004, 6, 483-495.
34. Nakano Y.; Addison WN.; Kaartinen MT. ATP-mediated mineralization of MC3T3-E1 osteoblast cultures. Bone, 2007, 41, 549-561.
35. Pellegatti P.; Falzoni S.; Pinton P.; Rizzuto R.; Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol. Biol. Cell, 2005, 16, 3659-3665.
36. Ohlendorff SD.; Tofteng CL.; Jensen JE.; Petersen S.; Civitelli R.; Fenger M. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics, 2007, 17, 555-567.
37. Panupinthu N.; Zhao L.; Possmayer F.; Ke HZ.; Sims SM.; Dixon SJ. P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. J. Biol. Chem., 2007, 282, 3403-3412.
38. Morrison MS.; Turin L.; King BF.; Burnstock G.; Arnett TR. ATP is a potent stimulator of the activation and formation of rodent osteoclasts. J. Physiol., 1998, 511, (Pt 2)495-500.
39. Wildman SS.; King BF.; Burnstock G. Zn2+ modulation of ATPresponses at recombinant P2X2 receptors and its dependence on extracellular pH. Br. J. Pharmacol., 1998, 123, 1214-1220.
40. Steinberg TH.; Hiken JF. P2 receptors in macrophage fusion and osteoclast formation. Purinergic Signal, 2007, 3, 53-57.
41. Lemaire I.; Falzoni S.; Leduc N.; Zhang B.; Pellegatti P.; Adinolfi E. Involvement of the purinergic P2X7 receptor in the formation of multinucleated giant cells. J. Immunol., 2006, 177, 7257-7265.
42. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone, 1998, 23, 75-81.
43. Gartland A.; Buckley KA.; Hipskind RA.; Perry MJ.; Tobias JH.; Buell G. Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Crit. Rev. Eukaryot. Gene Expr., 2003, 13, 243-253.
44. Hiken JF.; Steinberg TH. ATP downregulates P2X7 and inhibits osteoclast formation in RAW cells. Am. J. Physiol. Cell Physiol., 2004, 287, C403-C412.
45. Pellegatti P.; Falzoni S.; Donvito G.; Lemaire I.; Di VF. P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J., 2011, 25, 1264-1274.
46. Korcok J.; Sims SM.; Dixon SJ. P2X7 nucleotide receptors act through two distinct mechanisms to regulate osteoclast survival. J. Bone. Miner. Res., 2004, 19, S418.
47. Jorgensen NR.; Geist ST.; Civitelli R.; Steinberg TH. ATP- and gap junction-dependent intercellular calcium signaling in osteoblastic cells. J. Cell Biol. 1997, 139, 497-506.
48. Henriksen Z.; Hiken JF.; Steinberg TH.; Jorgensen NR. The predominant mechanism of intercellular calcium wave propagation changes during long-term culture of human osteoblast-like cells. Cell Calcium, 2006, 39, 435-444.
49. Jorgensen NR.; Henriksen Z.; Sorensen OH.; Eriksen EF.; Civitelli R.; Steinberg TH. Intercellular Calcium Signaling Occurs between Human Osteoblasts and Osteoclasts and Requires Activation of Osteoclast P2X7 Receptors. J. Biol. Chem., 2002, 277, 7574-7580.
50. Hazama R.; Qu X.; Yokoyama K.; Tanaka C.; Kinoshita E.; He J. ATP-induced osteoclast function: the formation of sealing-zone like structure and the secretion of lytic granules via microtubuledeacetylation under the control of Syk. Genes Cells, 2009, 14, 871-84.
51. Li J.; Liu D.; Ke HZ.; Duncan RL.; Turner CH. The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J. Biol. Chem., 2005, 280, 42952-42959.
52. Di VF. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol. Sci., 2007, 28, 465-472.
53. Ghiringhelli F.; Apetoh L.; Tesniere A.; Aymeric L.; Ma Y.; Ortiz C. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med., 2009, 15, 1170-1178.
54. Chen L.; Brosnan CF. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J. Immunol., 2006, 176, 3115-3126.
55. Nicke A.; Kuan YH.; Masin M.; Rettinger J.; Marquez-Klaka B.; Bender O. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knockout mice. J. Biol. Chem., 2009, 284, 25813-2522.
56. Taylor SR.; Gonzalez-Begne M.; Sojka DK.; Richardson JC.; Sheardown SA.; Harrison SM. Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J. Leukoc. Biol., 2009, 85, 978-86.
57. Syberg S.; Schwarz P.; Petersen S.; Steinberg TH.; Jensen JE.; Teilmann J. Association between P2X7 Receptor Polymorphisms and Bone Status in Mice. J. Osteoporos., 2012, 637986.
58. Hansen RR.; Nielsen CK.; Nasser A.; Thomsen SI.; Eghorn LF.; Pham Y. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain, 2011, 152, 1766-1776.
59. Solle M.; Labasi J.; Perregaux DG.; Stam E.; Petrushova N.; Koller BH. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem., 2001, 276, 125-132.
60. Chessell IP.; Hatcher JP.; Bountra C.; Michel AD.; Hughes JP.; Green P. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain, 2005, 114, 386-396.
61. Aspden RM.; Scheven BA.; Hutchison JD. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet, 2001, 357, 1118-1120.
62. Syberg S.; Petersen S.; Beck Jensen JE.; Gartland A.; Teilmann J.; Chessell I. Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice. J. Osteoporos., 2012, 2012, 391097.
63. Viecilli RF.; Katona TR.; Chen J.; Hartsfield JK Jr. Roberts WE. Orthodontic mechanotransduction and the role of the P2X7 receptor. Am. J. Orthod. Dentofacial. Orthop. 2009, 135, 694-16.
64. Li J.; Meyer R.; Duncan RL.; Turner CH. P2X7 nucleotide receptor plays an important role in callus remodeling during fracture repair. Calcif. Tissue Int., 2009, 84, 405-412.
65. Ralston SH.; de CB. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev., 2006, 20, 2492-2506.
66. Cabrini G.; Falzoni S.; Forchap SL.; Pellegatti P.; Balboni A.; Agostini P. A His-155 to Tyr polymorphism confers gain-offunction to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol., 2005, 175, 82-89.
67. Gu BJ.; Zhang W.; Worthington RA.; Sluyter R.; Dao-Ung P, Petrou S. A glu-496 to ala polymorphism leads to loss of function of the human p2x7 receptor. J. Biol. Chem., 2001, 276, 11135-11142.
68. Dao-Ung LP.; Fuller SJ.; Sluyter R.; Skarratt KK.; Thunberg U.; Tobin G. Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia. Br. J. Haematol., 2004, 125, 815-817.
69. Sluyter R.; Shemon AN.; Wiley JS. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J. Immunol., 2004, 172, 3399-3405.
70. Sluyter R.; Dalitz JG.; Wiley JS. P2X7 receptor polymorphism impairs extracellular adenosine 5'-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun., 2004, 5, 588-91.
71. Le Stunff H.; Auger R.; Kanellopoulos J.; Raymond MN. The Pro-451 to Leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. J. Biol. Chem. 2004, 279, 16918-26.
72. Wesselius A.; Bours MJ.; Henriksen Z.; Syberg S.; Petersen S.; Schwarz P. Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Osteoporos. Int. 2013, 24, 1235-1246.
73. Wiley JS.; Dao-Ung LP.; Li C.; Shemon AN.; Gu BJ.; Smart ML. An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J. Biol. Chem. 2003, 278, 17108-17113.
74. Jorgensen NR.; Husted LB.; Skarratt KK.; Stokes L.; Tofteng CL.; Kvist T. Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur. J. Hum. Genet. 2012, 20, 675-81.
75. Nissen N.; Madsen JS.; Bladbjerg EM.; Beck Jensen JE.; Jorgensen NR.; Langdahl B. No association between hip geometry and four common polymorphisms associated with fracture: the Danish osteoporosis prevention study. Calcif Tissue Int., 2009, 84, 276-285.
76. Gartland A.; Skarratt KK.; Hocking LJ.; Parsons C.; Stokes L.; Jorgensen NR. Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur. J. Hum. Genet., 2012, 20, 559-564.
77. Mrazek F.; Gallo J.; Stahelova A.; Petrek M. Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: a preliminary study. Hum. Immunol., 2010, 71, 201-205.
78. Vangsted A.; Klausen T.; Gimsing P.; Abildgaard N.; Andersen NF.; Gang AO. Genetic variants in the P2RX7gene are associated with risk of multiple myeloma. Eur. J. Haematol, 2014.
79. Stokes L.; Scurrah K.; Ellis JA.; Cromer BA.; Skarratt KK.; Gu BJ. A loss-of-function polymorphism in the human P2X4 receptor is associated with increased pulse pressure. Hypertension, 2011, 58, 1086-1092.
80. Wesselius A.; Bours MJ.; Jorgensen NR.; Wiley J.; Gu B.; van HS. Non-synonymous polymorphisms in the P2RX (4) are related to bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Purinergic Signal, 2013, 9, 123-130.
81. Stokes L.; Fuller SJ.; Sluyter R.; Skarratt KK.; Gu BJ.; Wiley JS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1{beta} secretion. FASEB J., 2010.
82. Hardy R.; Cooper MS. Bone loss in inflammatory disorders. J. Endocrinol., 2009, 201, 309-320.
83. Schett G.; David JP. The multiple faces of autoimmune-mediated bone loss. Nat. Rev. Endocrinol., 2010, 6, 698-706.
84. Kvist TM.; Schwarz P.; Jorgensen NR. The P2X7 receptor: a key player in immune-mediated bone loss? Scientific World Journal, 2014, 2014:954530.
85. Guile SD.; Alcaraz L.; Birkinshaw TN.; Bowers KC.; Ebden MR.; Furber M. Antagonists of the P2X(7) receptor. From lead identification to drug development. J. Med. Chem., 2009, 52, 3123-3141.
86. Gum RJ.; Wakefield B.; Jarvis MF. P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signal, 2012, 8, 41-56.
87. Liu L, Zou J, Liu X, Jiang LH, Li J. Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor. Eur. J. Pharmacol., 2010, 640, 15-19.
88. Jelassi B.; Anchelin M.; Chamouton J.; Cayuela ML.; Clarysse L.; Li J. Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis, 2013, 34, 1487-1496.
89. Keystone EC.; Wang MM.; Layton M.; Hollis S.; McInnes IB. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis., 2012, 71, 1630-1635.
90. Stock TC.; Bloom BJ.; Wei N.; Ishaq S.; Park W.; Wang X. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J. Rheumatol, 2012, 39, 720-727.
91. Nakamura E.; Uezono Y.; Narusawa K.; Shibuya I.; Oishi Y.; Tanaka M. ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. Am. J. Physiol. Cell. Physiol., 2000, 279, C510-C519.
92. Ihara H, Hirukawa K, Goto S, Togari A. ATP-stimulated interleukin-6 synthesis through P2Y receptors on human osteoblasts. Biochem. Biophys. Res. Commun., 2005, 326, 329-334.
93. Henriksen Z, Nissen N, Jørgensen NR. Functional P2X7 receptors are expressed in differentiated human osteoblasts. J. Bone Miner. Res., 2006, 14-19.
94. Qi J.; Chi L.; Faber J.; Koller B.; Banes AJ. ATP reduces gel compaction in osteoblast-populated collagen gels. J. Appl. Physiol., (1985) 2007, 102, 1152-1160.
95. Orriss IR.; Utting JC.; Brandao-Burch A.; Colston K.; Grubb BR.; Burnstock G. Extracellular Nucleotides Block Bone Mineralization in Vitro: Evidence for Dual Inhibitory Mechanisms Involving Both P2Y2 Receptors and Pyrophosphate. Endocrinology, 2007, 148, 4208-4216.
96. Orriss IR.; Knight GE.; Ranasinghe S.; Burnstock G.; Arnett TR. Osteoblast responses to nucleotides increase during differentiation. Bone, 2006, 39, 300-309.
97. Naemsch LN.; Du X.; Sims SM.; Dixon SJ. P2 nucleotide receptors in osteoclasts. Drug Development Research, 2001, 53, 130-139.
98. Naemsch LN.; Weidema AF.; Sims SM.; Underhill TM.; Dixon SJ. P2X(4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J. Cell Sci., 1999, 112, (Pt 23), 4425-35.
99. Skarratt KK.; Fuller SJ.; Sluyter R.; Dao-Ung LP.; Gu BJ.; Wiley JS. A 5' intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1-2% of the Caucasian population. FEBS. Lett., 2005, 579, 2675-2678.
100. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA et al. Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychi Res. 2010.
101. Sun C.; Chu J.; Singh S.; Salter RD. Identification and characterization of a novel variant of the human P2X7 receptor resulting in gain of function. Purinergic Signal, 2010.
102. Stokes L.; Fuller SJ.; Sluyter R.; Skarratt KK.; Gu BJ.; Wiley JS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1{beta} secretion. FASEB J., 2010.
103. Gu BJ.; Sluyter R.; Skarratt KK.; Shemon AN.; Dao-Ung LP.; Fuller SJ. An Arg307 to Gln polymorphism within the ATPbinding site causes loss of function of the human P2X7 receptor. J. Biol. Chem., 2004, 279, 31287-31295.
104. Shemon AN.; Sluyter R.; Fernando SL.; Clarke AL.; Dao-Ung LP.; Skarratt KK. A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem., 2006, 281, 2079-2086.
105. Wiley JS.; Dao-Ung LP.; Gu BJ.; Sluyter R.; Shemon AN.; Li C. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet, 2002, 359, 1114-1119.